Should we screen patients with hematologic malignancies for COVID-19?

Elie Rassy, Rita Maria Khoury-Abboud, Nathalie Ibrahim, Tarek Assi, Bachar Samra, Colette Hanna, Fadi El Karak, Marwan Ghosn

Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

Résumé

The coronavirus disease (COVID-19) pandemic has posed several challenges to the hematology community to re-organize the medical care of patients with hematologic malignancies. Whereas the oncology societies favored a more or less conservative approach which considered the possibility of delaying treatment administration on a case-by-case basis, the hematology community guidelines were less stringent and recommended adequate individualized regimens. As countries are de-escalating the lockdown and the medical community is unable to foresee the end of the current outbreak will and whether the pandemic would eventually come back as a seasonal infection, there is interest in screening of patients with hematology malignancies with COVID-19 instead of limiting access to curative treatments. The rapidly accumulating knowledge about COVID-19 allows a better understanding of the diagnostic tools that may be potentially used in screening. Herein, we briefly review the pathophysiology of COVID-19, the rationale of screening of patients with hematologic malignancies, tools for screening, and available guidelines.

langue originaleAnglais
Pages (de - à)648-653
Nombre de pages6
journalHematological oncology
Volume38
Numéro de publication5
Les DOIs
étatPublié - 1 déc. 2020
Modification externeOui

Contient cette citation